Company: JUNS
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001641172-25-024684
Chunk: 20

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-08-19
Form: 10-Q
Item: Item 8
Chunk 20
---
 from Within”,
are slated to hit the market in the third quarter of 2025 through a Direct-to-Consumer model. The Company will form a wholly-owned subsidiary
to focus on the consumer market, and will market its products on a to-be-developed website targeting the US market, along with social
media marketing. Internationally, the Company is focusing on partners who can market and accelerate sales, with an initial focus on the
Asian region.

The Company operates through
two segments: (i) the sale of premium nutritional supplements under the Nugevia brand, and (ii) pharmaceutical operations centered on
the development of drug candidates.

Financial
Position

The accompanying condensed consolidated financial
statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America
(“U.S. GAAP”). U.S GAAP contemplates the continuation of the Company as a going concern. The Company has had no revenues from product sales since inception and incurred a net loss of $3,781,832 and had
negative cash flows of operations totaling $1,891,263 for the six months ended June 30, 2025, and a cumulative net loss since inception
totaling $29,803,961.

In management’s opinion,
these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve
months from the date of this report. The Company plans to finance future operations with proceeds from equity securities, grant awards
and strategic collaborations. However, there is no assurance that the Company will be able to affect transactions on commercially reasonable
terms, if at all.

Results
of Operations

Three
Months Ended June 30, 2025 Compared to the Three Months Ended June 30, 2024

Research
and Development Expenses

Research
and development (“R&D”) expenses were $759,448 for three months ended June 30, 2025 compared to $101,077 for three months
ended June 30, 2024, representing an increase of $658,371, or 651%. The increase in research and development expenses was primarily
driven by costs incurred under a three-year service agreement associated with product development and distribution efforts in the Southeast
Asian market. The remainder of the increase relates to heightened R&D activities, specifically the procurement of clinical trial
supplies for our Parkinson’s disease program.

General
and Administrative Expenses

General
and administrative expenses were $1,505,432 for the